Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 2Phase 3 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 2Dermatologic 1CNS 1

Conditions

Rectal Neoplasms 1Pancreatic Neoplasms 1Colonic Neoplasms 1

Interventions

Gemcitabine 153Oxaliplatin 124Fluorouracil 108Capecitabine 105pembrolizumab 92Bevacizumab 79Leucovorin 76Irinotecan 72Nivolumab 70130-nm albumin-bound paclitaxel 68Paclitaxel 62Cisplatin 62Cetuximab 60Cyclophosphamide 47Albumin-Bound Paclitaxel 45Radiotherapy 39Docetaxel 36durvalumab 33Sorafenib 32Taxes 29Carboplatin 27fludarabine 26tislelizumab 25Drug Therapy 25atezolizumab 23Folfox protocol 23regorafenib 20lenvatinib 19Ipilimumab 19sintilimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × nintedanib × Gastrointestinal × Clear all
NCT02902484 2024-06-03

Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer

University of Texas Southwestern Medical Center

Phase 1/2 Terminated
14 enrolled 9 charts
Gastrointestinal

Pancreatic Neoplasms

NCT02393755 2021-07-08

Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer

Roswell Park Cancer Institute

Phase 1/2 Completed
42 enrolled 16 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡